The company develops the Tailored Leukapheresis (TLA) immunotherapy for immune mediated inflammatory diseases (IMIDs), which has demonstrated proof-of-concept in a Phase I/II clinical trial on inflammatory bowel disease (IBD). TLA was granted € 2.7M from the SME Instrument HORIZON 2020, phase 2. GAEU helped structuring the project, limiting the scope and building business argumentation. We made a grand contribution to the successful process by preparing the client for the pitch deck and interview in Brussels. We also created the presentation needed.